List of Excipients in Branded Drug PERTZYE

Pertzye Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Pertzye is a delayed-release pancrelipase product whose commercial value depends on enzyme stability, enteric protection, dose flexibility, and reliable release across the gastrointestinal tract. The largest excipient opportunities are in improved multiparticulate coatings, capsule technology, storage protection, dose customization, and lower-cost manufacturing rather than in creating a new active pharmaceutical ingredient.

Pertzye is marketed by Chiesi USA and was originally developed by Digestive Care. The product is FDA-approved for exocrine pancreatic insufficiency associated with cystic fibrosis, chronic pancreatitis, pancreatectomy, and other conditions.[1] It is a non-biologic pancreatic enzyme replacement therapy, so biosimilar pathways do not apply. Generic competition would proceed through an abbreviated new drug application or other applicable FDA pathway.

What is Pertzye and how does its formulation work?

Pertzye contains pancrelipase, a mixture of porcine-derived lipase, protease, and amylase. Its dosage strength is expressed primarily in USP lipase units. The product is supplied as delayed-release capsules containing enteric-coated microspheres.

Product attribute	Pertzye characteristic
Active ingredient	Pancrelipase
Enzyme components	Lipase, protease, amylase
Dosage form	Delayed-release capsule
Internal dosage form	Enteric-coated microspheres
Primary site of action	Small intestine
FDA indication	Exocrine pancreatic insufficiency
Key formulation objective	Protect enzymes from gastric acid and release them in the intestine
Commercial dosage strengths	Multiple lipase-unit strengths, including 4,000, 8,000, 16,000, and 24,000 lipase-unit capsules
Regulatory pathway	NDA
Biosimilar relevance	None

The formulation has two performance requirements. First, the enzymes must remain stable during storage and passage through the stomach. Second, the microspheres must release enzyme rapidly enough after exposure to the higher-pH intestinal environment.

Pertzye’s label identifies excipients associated with the microspheres, coating system, and capsule shell. Public labeling identifies excipient classes including hypromellose, microcrystalline cellulose, croscarmellose sodium, crospovidone, magnesium stearate, talc, colloidal silicon dioxide, sodium lauryl sulfate, and triethyl citrate, together with capsule-shell materials and permitted colorants.[1]

What excipients are used in Pertzye?

Pertzye’s excipient system can be divided into four functional groups.

Core-forming and enzyme-stabilizing excipients

Microcrystalline cellulose and related inert carriers provide the particle substrate or structural matrix. Crospovidone and croscarmellose sodium can support water penetration and dispersion, although their exact contribution depends on the manufacturing process and particle architecture.

Colloidal silicon dioxide can improve powder flow and reduce agglomeration during processing. Magnesium stearate functions as a lubricant but must be controlled because excessive lubrication can reduce wetting and slow dispersion.

Enzyme products require tighter control than many conventional oral solids. Pancrelipase is a mixture of proteins and is vulnerable to moisture, heat, shear, and interfacial stress. Excipient changes can affect enzyme potency, particle morphology, and dissolution even when the nominal composition remains similar.

Enteric-coating excipients

Hypromellose and methacrylic-acid-based polymers are central to delayed-release performance in pancreatic enzyme products. The enteric layer must resist acidic gastric conditions and dissolve at the target intestinal pH.

Triethyl citrate is used as a plasticizer in enteric-coating systems. It improves film flexibility and reduces cracking during drying, filling, transport, and storage. Talc can act as an anti-tacking and processing aid in coating operations.

The commercial opportunity is to optimize polymer grade, plasticizer concentration, coating weight, and curing conditions. These variables influence acid resistance, pH-triggered dissolution, enzyme recovery, and batch-to-batch consistency.

Capsule-shell excipients

The hard capsule shell normally contains gelatin, titanium dioxide, and colorants. Capsule-shell selection affects moisture transmission, mechanical integrity, visual differentiation between strengths, and compatibility with high-throughput filling equipment.

A vegetarian or hypromellose capsule could create a differentiated product, but the change would require comparative stability, dissolution, compatibility, and potentially clinical bridging work. It would not automatically create freedom from formulation patents or regulatory obligations.

Surfactants and wetting aids

Sodium lauryl sulfate or comparable wetting agents can improve dispersion of hydrophobic or poorly wetting coating components. The level must remain tightly controlled because surfactants can affect enzyme release, gastrointestinal tolerability, and coating integrity.

What formulations are protected by Pertzye’s intellectual property?

The relevant intellectual-property category is the pancreatic enzyme formulation rather than a conventional small-molecule composition-of-matter patent. Potentially protectable features include:

1. Enteric-coated pancrelipase microspheres.
2. Defined enzyme-to-excipient ratios.
3. Acid-resistant coating systems.
4. pH-triggered release profiles.
5. Particle-size distributions.
6. Manufacturing methods for enzyme-loaded particles.
7. Stabilization methods that preserve lipase activity.
8. Methods of administering enzyme particles with food.
9. Dose-specific capsule configurations.

The strongest formulation claims would typically require a combination of composition and performance limitations. A claim directed only to the use of an enteric polymer or a common plasticizer would be easier to design around than a claim requiring a specific particle structure, coating weight, dissolution profile, and retained enzyme activity.

How strong is the Pertzye patent estate?

Pertzye’s patent strength is likely concentrated in formulation and manufacturing claims rather than active-ingredient exclusivity. Pancrelipase has been used clinically for decades, limiting the scope for broad composition-of-matter protection.

The relevant diligence points are:

IP issue	Commercial implication
Pancrelipase is established technology	Limited opportunity for broad active-ingredient claims
Multiparticulate delivery	Potential protection for particle architecture and release
Enteric coating	Design-around risk is significant because multiple polymers are available
Enzyme stabilization	Stronger value if linked to measurable shelf-life or potency benefits
Dose strengths	Usually weak as standalone patent subject matter
Manufacturing process	Can create barriers if the process materially improves yield or activity
Method of use	Possible protection for dosing, administration, or disease-specific use
Trade secrets	Important for coating process parameters and enzyme handling

A live patent-by-patent freedom-to-operate conclusion requires review of current USPTO records, FDA Orange Book listings, prosecution histories, assignments, and terminal disclaimers. Public FDA labeling confirms the regulatory formulation but does not establish the full scope or current enforceability of every patent claim.

When did Pertzye lose regulatory exclusivity?

Pertzye received FDA approval in April 2012 under NDA 200698.[1] Pancrelipase was not a new molecular entity in the ordinary small-molecule sense. The product therefore did not receive the standard five-year NCE exclusivity associated with a new active ingredient.

The principal regulatory exclusivity relevant to an approved reformulated or previously known active ingredient would generally be three-year exclusivity for new clinical investigations, where granted. That period would not block all development activity, but it could delay approval of certain competing applications relying on the protected clinical data.

Pertzye’s principal commercial protection is therefore more dependent on patents, formulation know-how, manufacturing controls, physician familiarity, reimbursement access, and patient switching friction than on long-duration regulatory exclusivity.

What is the Orange Book status of Pertzye?

Pertzye is an NDA product listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.[2] The Orange Book is the primary FDA source for listed patents and patent-use codes associated with an NDA.

For a generic applicant, the relevant questions are:

• Whether any Pertzye patent remains listed.
• Whether the patent claims the formulation, method of use, or both.
• Whether the proposed product can be approved with a Paragraph IV certification.
• Whether the reference-product sponsor files patent litigation within the statutory period.
• Whether an authorized generic or settlement changes the commercial launch date.

A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. Litigation can trigger a 30-month stay of approval under the Hatch-Waxman framework, subject to statutory exceptions and court developments.[3]

Which companies are challenging Pertzye?

The principal competitive risk comes from other pancreatic enzyme replacement therapies rather than from biosimilars. The principal branded competitors include:

Product	Company	Dosage form	Competitive position
Creon	AbbVie	Delayed-release capsules and other presentations	Large installed base and broad physician recognition
Zenpep	Nestlé Health Science	Delayed-release capsules	Direct pancrelipase competitor
Pancreaze	Vivus	Delayed-release capsules	Direct pancrelipase competitor
Ultresa	Historical product	Delayed-release capsules	Prior market participant
Generic pancrelipase products	Multiple potential applicants	Product-specific	Price and formulary pressure

Competition is based on lipase-unit dosing, capsule strength, insurance coverage, patient support, physician familiarity, and ability to maintain enzyme activity through gastric transit. Enzyme replacement products are not readily interchangeable from a practical clinical perspective even when they contain the same active ingredient class.

What excipient opportunities exist for Pertzye competitors?

Lower-cost enteric-coating systems

A competitor can evaluate methacrylic-acid copolymers, cellulose-based enteric polymers, or combinations of polymers and plasticizers. The objective is to achieve equivalent acid resistance and intestinal release at lower coating weight, shorter processing time, or reduced solvent burden.

Potential economic benefits include:

• Lower polymer consumption.
• Reduced coating-cycle duration.
• Lower energy use.
• Improved batch throughput.
• Reduced product loss during coating.
• Better scalability from development to commercial production.

The main barrier is the need to demonstrate equivalent dissolution and enzyme activity. A lower-cost excipient is commercially useful only if it preserves performance across the product shelf life.

Moisture-barrier capsule systems

Capsule-shell and packaging changes can improve stability in humid climates and reduce dependence on high-cost desiccants. Options include hypromellose shells, lower-moisture gelatin grades, high-barrier blister packaging, and optimized bottle-closure systems.

Packaging is a major commercial opportunity because pancrelipase products can be sensitive to moisture. A formulation with equivalent initial potency but inferior moisture protection can produce downstream loss of activity and product complaints.

Dose-flexible multiparticulates

Pertzye’s microsphere architecture allows the product to be administered with food and, where permitted by labeling, opened and mixed with suitable acidic soft foods. A competitor could develop smaller particles, sprinkle formulations, pediatric sachets, or unit-dose packets.

These formats may improve use in:

• Infants and young children.
• Patients with feeding tubes.
• Patients unable to swallow capsules.
• Patients requiring individualized enzyme dosing.
• Hospital and home-care settings.

The regulatory burden increases when particle size, capsule opening, food mixing, or tube administration changes the exposure profile.

Improved enzyme stabilization

Stabilization strategies may include optimized pH control, low-water-activity excipient systems, antioxidants where justified, protein-compatible surfactants, and tighter control of residual solvents and moisture.

The strongest commercial proposition would be a documented improvement in labeled shelf life, reduced potency variability, or improved enzyme recovery after storage. A formulation change without a measurable patient or manufacturing benefit is unlikely to support premium pricing.

What generic launch risks exist for Pertzye?

A generic entrant faces four principal risks.

First, therapeutic equivalence is more complex than matching the capsule strength. Lipase, protease, and amylase activities must be controlled separately, and the product must demonstrate appropriate delayed-release behavior.

Second, enzyme activity can vary with manufacturing conditions. Changes in granulation, coating, drying, or storage can affect potency and dissolution.

Third, the reference sponsor may assert formulation or method-of-use patents. The applicant must assess listed patents and broader non-listed patent claims before launch.

Fourth, market access is concentrated. Creon and Zenpep have established reimbursement positions, while a new entrant would need contracting leverage, supply reliability, and evidence that switching does not increase treatment failures or patient-management costs.

What licensing deals could create value?

Licensing opportunities are most credible in enabling technologies rather than in the pancrelipase active ingredient itself. Relevant assets include:

• Proprietary enzyme stabilization systems.
• Low-moisture capsule technology.
• High-throughput enteric-coating equipment.
• Unit-dose pediatric delivery systems.
• Tube-compatible multiparticulates.
• Continuous manufacturing methods.
• Analytical methods for simultaneous lipase, protease, and amylase release.
• Polymer systems that reduce coating weight or solvent use.

A licensor with a validated coating process may offer greater value than a licensor with a broad but unvalidated excipient patent. Commercial diligence should focus on scale-up data, retained enzyme activity, dissolution robustness, patent term, and whether the technology can be used without infringing Pertzye or competitor claims.

What patent litigation affects Pertzye?

Pertzye-related litigation risk is primarily a Hatch-Waxman issue involving potential ANDA applicants. The relevant events are a Paragraph IV notice, a patent-infringement complaint, a 30-month stay, settlement terms, and any authorized-generic arrangement.

Public FDA and court databases should be reviewed for current cases, but the commercial conclusion is clear: the absence of a prominent active-ingredient patent does not eliminate litigation risk. Formulation and process patents can delay approval or force a non-infringing design-around.

How does Pertzye compare with Creon and Zenpep?

Factor	Pertzye	Creon	Zenpep
Active ingredient	Pancrelipase	Pancrelipase	Pancrelipase
Core technology	Delayed-release microspheres	Delayed-release minimicrospheres	Delayed-release particles
Main differentiation	Dose flexibility and formulation profile	Scale, broad market adoption, reimbursement reach	Established direct competitor
Excipient opportunity	Coating, stabilization, pediatric delivery	Manufacturing efficiency and life-cycle management	Cost reduction and formulation differentiation
Generic risk	Moderate to high	High because of market size	Moderate to high
Biosimilar risk	None	None	None

The largest commercial opportunity is not necessarily to replicate Pertzye exactly. A differentiated product could compete through pediatric administration, unit-dose packaging, lower total treatment cost, reduced pill burden, or improved performance under variable gastric and intestinal conditions.

Key Takeaways

• Pertzye is a pancrelipase delayed-release capsule containing enteric-coated microspheres.
• Its excipient strategy depends on enzyme stabilization, moisture control, enteric protection, and reliable intestinal release.
• The most commercially valuable excipient innovations are likely to involve coating efficiency, storage stability, pediatric delivery, and manufacturing scale.
• Pertzye does not face biosimilar competition because it is a non-biologic enzyme product.
• Generic risk is driven by formulation equivalence, patent scope, manufacturing reproducibility, and reimbursement access.
• The strongest licensing targets are validated enzyme-stabilization, coating, packaging, and multiparticulate-delivery technologies.
• Orange Book and patent-court review is required for a current patent-expiration and Paragraph IV assessment.

FAQs

Can a Pertzye competitor use a different enteric polymer?

Yes. A competitor can use a different polymer or polymer combination if the product meets FDA requirements for pharmaceutical quality, stability, dissolution, enzyme activity, and therapeutic equivalence. The alternative must also avoid applicable patent claims.

Is Pertzye interchangeable with Creon or Zenpep?

Not automatically. The products contain pancrelipase but may differ in particle structure, enzyme activity ratios, release behavior, capsule strengths, and labeling. Substitution depends on the applicable FDA equivalence determination, state law, payer policy, and prescriber direction.

Can Pertzye microspheres be reformulated into a tablet?

A tablet would be technically possible but commercially and regulatorily difficult. Compression could damage enzyme-containing particles, alter coating integrity, and create unacceptable gastric release. Multiparticulate capsules remain better aligned with the product’s delivery requirements.

Which excipient creates the greatest formulation risk?

The enteric-coating system creates the greatest risk because polymer grade, plasticizer level, coating thickness, curing, and moisture exposure directly affect acid resistance and intestinal release.

What is the best commercial niche for a new pancrelipase product?

Pediatric and tube-administration formats offer the clearest differentiation potential. Unit-dose packets, sprinkle formulations, smaller particles, improved moisture protection, and reduced treatment burden could support market access beyond a price-only generic strategy.

References

1. U.S. Food and Drug Administration. (2023). Pertzye (pancrelipase) delayed-release capsules: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
4. Chiesi USA, Inc. (2024). Pertzye product information and patient administration materials.